{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:43:30Z","timestamp":1791287010654,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science and Technology Council, Taiwan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bcr-Abl transformation leads to chronic myeloid leukemia (CML). The acquirement of T315I mutation causes tyrosine kinase inhibitors (TKI) resistance. This study develops a compound, JMF4073, inhibiting thymidylate (TMP) and cytidylate (CMP) kinases, aiming for a new therapy against TKI-resistant CML. In vitro and in vivo treatment of JMF4073 eliminates WT-Bcr-Abl-32D CML cells. However, T315I-Bcr-Abl-32D cells are less vulnerable to JMF4073. Evidence is presented that ATF4-mediated upregulation of GSH causes T315I-Bcr-Abl-32D cells to be less sensitive to JMF4073. Reducing GSH biosynthesis generates replication stress in T315I-Bcr-Abl-32D cells that require dTTP\/dCTP synthesis for survival, thus enabling JMF4073 susceptibility. It further shows that the levels of ATF4 and GSH in several human CML blast-crisis cell lines are inversely correlated with JMF4073 sensitivity, and the combinatory treatment of JMF4073 with GSH reducing agent leads to synthetic lethality in these CML blast-crisis lines. Altogether, the investigation indicates an alternative option in CML therapy.<\/jats:p>","DOI":"10.1038\/s42003-024-06547-1","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T18:01:35Z","timestamp":1720634495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Glutathione determines chronic myeloid leukemia vulnerability to an inhibitor of CMPK and TMPK"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-2085","authenticated-orcid":false,"given":"Chang-Yu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsuan","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Jung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim-Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Mei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-284X","authenticated-orcid":false,"given":"Zee-Fen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"6547_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley, J. D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290\u2013293 (1973).","journal-title":"Nature"},{"key":"6547_CR2","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330\u20131340 (1999).","journal-title":"N. Engl. J. Med."},{"key":"6547_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172\u2013183 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"6547_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1182\/blood.V99.4.1388","volume":"99","author":"JF Dorsey","year":"2002","unstructured":"Dorsey, J. F., Cunnick, J. M., Mane, S. M. & Wu, J. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. Blood 99, 1388\u20131397 (2002).","journal-title":"Blood"},{"key":"6547_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","volume":"1","author":"M Sattler","year":"2002","unstructured":"Sattler, M. et al. Critical role for Gab2 in transformation by BCR\/ABL. Cancer Cell 1, 479\u2013492 (2002).","journal-title":"Cancer Cell"},{"key":"6547_CR6","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie, S. et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188\u20136195 (2001).","journal-title":"Oncogene"},{"key":"6547_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun, T. P., Eide, C. A. & Druker, B. J. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37, 530\u2013542 (2020).","journal-title":"Cancer Cell"},{"key":"6547_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566 (1996).","journal-title":"Nat. Med."},{"key":"6547_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031\u20131037 (2001).","journal-title":"N. Engl. J. Med."},{"key":"6547_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti, G., Castagnetti, F., Gugliotta, G. & Baccarani, M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat. Rev. Clin. Oncol. 14, 141\u2013154 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"6547_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/heartjnl-2020-318251","volume":"107","author":"D Leong","year":"2021","unstructured":"Leong, D. et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. Heart 107, 667\u2013673 (2021).","journal-title":"Heart"},{"key":"6547_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang, X. et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21, 926\u2013935 (2007).","journal-title":"Leukemia"},{"key":"6547_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319\u2013325 (2002).","journal-title":"Blood"},{"key":"6547_CR14","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3109\/10428194.2010.520774","volume":"51","author":"JC Chomel","year":"2010","unstructured":"Chomel, J. C. et al. Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk. Lymphoma 51, 2103\u20132111 (2010).","journal-title":"Leuk. Lymphoma"},{"key":"6547_CR15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.1140735","volume":"319","author":"TD Halazonetis","year":"2008","unstructured":"Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352\u20131355 (2008).","journal-title":"Science"},{"key":"6547_CR16","doi-asserted-by":"publisher","first-page":"R435","DOI":"10.1016\/j.cub.2014.04.012","volume":"24","author":"SA Hills","year":"2014","unstructured":"Hills, S. A. & Diffley, J. F. DNA replication and oncogene-induced replicative stress. Curr. Biol. 24, R435\u2013444, (2014).","journal-title":"Curr. Biol."},{"key":"6547_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.aao3172","volume":"358","author":"K Somyajit","year":"2017","unstructured":"Somyajit, K. et al. Redox-sensitive alteration of replisome architecture safeguards genome integrity. Science 358, 797\u2013802 (2017).","journal-title":"Science"},{"key":"6547_CR18","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","volume":"104","author":"MO Nowicki","year":"2004","unstructured":"Nowicki, M. O. et al. BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104, 3746\u20133753 (2004).","journal-title":"Blood"},{"key":"6547_CR19","doi-asserted-by":"publisher","first-page":"9906","DOI":"10.1021\/acs.jmedchem.6b01280","volume":"59","author":"YH Chen","year":"2016","unstructured":"Chen, Y. H. et al. Chemical inhibition of human thymidylate kinase and structural insights into the phosphate binding loop and ligand-induced degradation. J. Med. Chem. 59, 9906\u20139918 (2016).","journal-title":"J. Med. Chem."},{"key":"6547_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2012.04.038","volume":"22","author":"CM Hu","year":"2012","unstructured":"Hu, C. M. et al. Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. Cancer Cell 22, 36\u201350 (2012).","journal-title":"Cancer Cell"},{"key":"6547_CR21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.cmet.2022.08.017","volume":"34","author":"S Ahola","year":"2022","unstructured":"Ahola, S. et al. OMA1-mediated integrated stress response protects against ferroptosis in mitochondrial cardiomyopathy. Cell Metab. 34, 1875\u20131891.e1877 (2022).","journal-title":"Cell Metab."},{"key":"6547_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112724","volume":"42","author":"JKC Kress","year":"2023","unstructured":"Kress, J. K. C. et al. The integrated stress response effector ATF4 is an obligatory metabolic activator of NRF2. Cell Rep. 42, 112724 (2023).","journal-title":"Cell Rep."},{"key":"6547_CR23","doi-asserted-by":"publisher","unstructured":"Sarcinelli, C. et al. ATF4-dependent NRF2 transcriptional regulation promotes antioxidant protection during endoplasmic reticulum stress. Cancers (Basel) 12, https:\/\/doi.org\/10.3390\/cancers12030569 (2020).","DOI":"10.3390\/cancers12030569"},{"key":"6547_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330\u2013338 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"6547_CR25","doi-asserted-by":"publisher","first-page":"33882","DOI":"10.1074\/jbc.M401989200","volume":"279","author":"D Segura-Pena","year":"2004","unstructured":"Segura-Pena, D., Sekulic, N., Ort, S., Konrad, M. & Lavie, A. Substrate-induced conformational changes in human UMP\/CMP kinase. J. Biol. Chem. 279, 33882\u201333889 (2004).","journal-title":"J. Biol. Chem."},{"key":"6547_CR26","first-page":"1460","volume":"21","author":"U Matulonis","year":"1993","unstructured":"Matulonis, U., Salgia, R., Okuda, K., Druker, B. & Griffin, J. D. Interleukin-3 and p210 BCR\/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp. Hematol. 21, 1460\u20131466 (1993).","journal-title":"Exp. Hematol."},{"key":"6547_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401\u2013412 (2009).","journal-title":"Cancer Cell"},{"key":"6547_CR28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994\u20131004 (2003).","journal-title":"N. Engl. J. Med."},{"key":"6547_CR29","first-page":"1509","volume":"23","author":"B Jazwiec","year":"1995","unstructured":"Jazwiec, B., Mahon, F. X., Pigneux, A., Pigeonnier, V. & Reiffers, J. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells. Exp. Hematol. 23, 1509\u20131514 (1995).","journal-title":"Exp. Hematol."},{"key":"6547_CR30","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","volume":"82","author":"S Saxena","year":"2022","unstructured":"Saxena, S. & Zou, L. Hallmarks of DNA replication stress. Mol. Cell 82, 2298\u20132314 (2022).","journal-title":"Mol. Cell"},{"key":"6547_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret, M. & Halazonetis, T. D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 10, 425\u2013448 (2015).","journal-title":"Annu. Rev. Pathol."},{"key":"6547_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat. Cell Biol. 16, 2\u20139 (2014).","journal-title":"Nat. Cell Biol."},{"key":"6547_CR33","doi-asserted-by":"publisher","unstructured":"Torrence, M. E. et al. The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals. Elife 10, https:\/\/doi.org\/10.7554\/eLife.63326 (2021).","DOI":"10.7554\/eLife.63326"},{"key":"6547_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1097-2765(03)00105-9","volume":"11","author":"HP Harding","year":"2003","unstructured":"Harding, H. P. et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619\u2013633 (2003).","journal-title":"Mol. Cell"},{"key":"6547_CR35","doi-asserted-by":"publisher","first-page":"111233","DOI":"10.1016\/j.celrep.2022.111233","volume":"40","author":"E Pranzini","year":"2022","unstructured":"Pranzini, E. et al. SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. Cell Rep. 40, 111233 (2022).","journal-title":"Cell Rep."},{"key":"6547_CR36","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/0006-2952(84)90598-7","volume":"33","author":"R Drew","year":"1984","unstructured":"Drew, R. & Miners, J. O. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem. Pharm. 33, 2989\u20132994 (1984).","journal-title":"Biochem. Pharm."},{"key":"6547_CR37","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.celrep.2019.07.098","volume":"28","author":"SC Tompkins","year":"2019","unstructured":"Tompkins, S. C. et al. Disrupting mitochondrial pyruvate uptake directs glutamine into the TCA cycle away from glutathione synthesis and impairs hepatocellular tumorigenesis. Cell Rep. 28, 2608\u20132619 e2606 (2019).","journal-title":"Cell Rep."},{"key":"6547_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19213-4","volume":"8","author":"M Sato","year":"2018","unstructured":"Sato, M. et al. The ferroptosis inducer erastin irreversibly inhibits system x(c)- and synergizes with cisplatin to increase cisplatin\u2019s cytotoxicity in cancer cells. Sci. Rep. 8, 968 (2018).","journal-title":"Sci. Rep."},{"key":"6547_CR39","doi-asserted-by":"publisher","first-page":"1607455","DOI":"10.1080\/23723556.2019.1607455","volume":"6","author":"P Pasero","year":"2019","unstructured":"Pasero, P. & Tourriere, H. Overexpression of the Fork Protection Complex: a strategy to tolerate oncogene-induced replication stress in cancer cells. Mol. Cell Oncol. 6, 1607455 (2019).","journal-title":"Mol. Cell Oncol."},{"key":"6547_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08886-8","volume":"10","author":"JN Bianco","year":"2019","unstructured":"Bianco, J. N. et al. Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner. Nat. Commun. 10, 910 (2019).","journal-title":"Nat. Commun."},{"key":"6547_CR41","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1074\/jbc.M115.692798","volume":"291","author":"AV Peskin","year":"2016","unstructured":"Peskin, A. V. et al. Glutathionylation of the active site cysteines of peroxiredoxin 2 and recycling by glutaredoxin. J. Biol. Chem. 291, 3053\u20133062 (2016).","journal-title":"J. Biol. Chem."},{"key":"6547_CR42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.tibs.2017.05.002","volume":"42","author":"D D\u2019Amico","year":"2017","unstructured":"D\u2019Amico, D., Sorrentino, V. & Auwerx, J. Cytosolic proteostasis networks of the mitochondrial stress response. Trends Biochem. Sci. 42, 712\u2013725 (2017).","journal-title":"Trends Biochem. Sci."},{"key":"6547_CR43","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1083\/jcb.201702058","volume":"216","author":"PM Quiros","year":"2017","unstructured":"Quiros, P. M. et al. Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals. J. Cell Biol. 216, 2027\u20132045 (2017).","journal-title":"J. Cell Biol."},{"key":"6547_CR44","doi-asserted-by":"publisher","unstructured":"Mick, E. et al. Distinct mitochondrial defects trigger the integrated stress response depending on the metabolic state of the cell. Elife 9, https:\/\/doi.org\/10.7554\/eLife.49178 (2020).","DOI":"10.7554\/eLife.49178"},{"key":"6547_CR45","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1172\/JCI78031","volume":"125","author":"S Dey","year":"2015","unstructured":"Dey, S. et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J. Clin. Invest 125, 2592\u20132608 (2015).","journal-title":"J. Clin. Invest"},{"key":"6547_CR46","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.tcb.2023.06.002","volume":"34","author":"S Ahola","year":"2024","unstructured":"Ahola, S. & Langer, T. Ferroptosis in mitochondrial cardiomyopathy. Trends Cell Biol. 34, 150\u2013160 (2024).","journal-title":"Trends Cell Biol."},{"key":"6547_CR47","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00204-024-03681-x","volume":"98","author":"H Tang","year":"2024","unstructured":"Tang, H., Kang, R., Liu, J. & Tang, D. ATF4 in cellular stress, ferroptosis, and cancer. Arch. Toxicol. 98, 1025\u20131041 (2024).","journal-title":"Arch. Toxicol."},{"key":"6547_CR48","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4161\/15384101.2014.987618","volume":"14","author":"N Tsao","year":"2015","unstructured":"Tsao, N., Lee, M. H., Zhang, W., Cheng, Y. C. & Chang, Z. F. The contribution of CMP kinase to the efficiency of DNA repair. Cell Cycle 14, 354\u2013363 (2015).","journal-title":"Cell Cycle"},{"key":"6547_CR49","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1101\/gad.1322905","volume":"19","author":"PY Ke","year":"2005","unstructured":"Ke, P. Y., Kuo, Y. Y., Hu, C. M. & Chang, Z. F. Control of dTTP pool size by anaphase promoting complex\/cyclosome is essential for the maintenance of genetic stability. Genes Dev. 19, 1920\u20131933 (2005).","journal-title":"Genes Dev."},{"key":"6547_CR50","doi-asserted-by":"publisher","first-page":"14247","DOI":"10.1021\/acs.analchem.1c03236","volume":"93","author":"HY Wang","year":"2021","unstructured":"Wang, H. Y., Hsin, P., Huang, C. Y. & Chang, Z. F. A convenient and sensitive method for deoxynucleoside triphosphate quantification by the combination of rolling circle amplification and quantitative polymerase chain reaction. Anal. Chem. 93, 14247\u201314255 (2021).","journal-title":"Anal. Chem."},{"key":"6547_CR51","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.celrep.2016.06.094","volume":"16","author":"CW Chen","year":"2016","unstructured":"Chen, C. W. et al. The impact of dUTPase on ribonucleotide reductase-induced genome instability in cancer cells. Cell Rep. 16, 1287\u20131299 (2016).","journal-title":"Cell Rep."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06547-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06547-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06547-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T19:08:33Z","timestamp":1720638513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06547-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6547"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-06547-1","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"843"}}